novo-nordisk-glp-1-konkurrenz-und-telemedizin-deal - Stock Newsroom

S TOCK newsroom .COM

S&P 500 6,839 +0.82%

DJIA 48,333 +0.89%

Nasdaq 25,088 +0.78%

DAX 23,923 -0.17%

Gold $4,196 +0.16%

Oil $95.71 -1.01%

BTC $72,439 +1.50%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,221 +0.58%

S&P 500 6,839 +0.82%

DJIA 48,333 +0.89%

Nasdaq 25,088 +0.78%

DAX 23,923 -0.17%

Gold $4,196 +0.16%

Oil $95.71 -1.01%

BTC $72,439 +1.50%

VIX 20.43 -15.85%

EUR/USD 1.1785 -0.02%

ETH $2,221 +0.58%

novo-nordisk-glp-1-konkurrenz-und-telemedizin-deal

Novo Nordisk GLP-1 competition visual with obesity pill and injectable pen contrasted on dark background

Pharma & Healthcare·Stocks·Europe

Novo Nordisk GLP-1 competition Warning with new pill rival

By Maik Kemper • Mar 17, 2026

Novo Nordisk GLP-1 competition visual with obesity pill and injectable pen contrasted on dark background

Pharma & Healthcare·Stocks·Europe

Novo Nordisk GLP-1 competition Warning with new pill rival

By Maik Kemper • Mar 17, 2026

Can Novo Nordisk defend its GLP-1 dominance as a potent oral rival emerges and a bold US telehealth deal reshapes distribution? How does Structure Therapeutics…